Published in Surgery Litigation and Law Weekly, March 6th, 2009
"Visual acuity improved front 20/70 to 20/20 and remained at this level for 32 months. In certain patients with choroidal neovascularization from angioid streaks, intravitreal bevacizumab ilia produce normalization of visual acuity and macular anatomy for an extended period of time," wrote J.L. Kovach and colleagues.
The researchers concluded: "[Ophthalmic Surg Lasers Imaging 2009;40:77-79.]'."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.